Cardiac Biomarkers Market Report 2026

Cardiac Biomarkers Market Overview

• Cardiac Biomarkers market size has reached to $21.19 billion in 2025 • Expected to grow to $42.21 billion in 2030 at a compound annual growth rate (CAGR) of 14.9% • Growth Driver: Healthcare Expenditure Surge Fuels Expansion Of The Cardiac Biomarker Market • Market Trend: Companies Expands Cardiac Biomarker Portfolio With Innovative Assays For Improved Cardiovascular Disease Management • North America was the largest region in 2025.

What Is Covered Under Cardiac Biomarkers Market?

Cardiac biomarkers are chemicals released by heart into the blood when it is injured or under stress. It used for the detection and measurement of various cardiac vascular diseases. The main types of cardiac biomarkers are creatine kinase (CK-MB), trophonins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), and others. Creatine kinase (CK) is an enzyme found in various tissues in the body, including muscle and brain tissue, used in the diagnosis of myocardial infarction (MI), commonly known as a heart attack. They are used at locations such as point-of-care testing and laboratory testing in a variety of applications, including testing for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), atherosclerosis, and others. These are used by hospitals and specialty clinics.

What Is The Cardiac Biomarkers Market Growth Forecast?

The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to $42.21 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing demand for rapid cardiac diagnostics, rising adoption of decentralized testing models, expansion of preventive cardiology screening, growing investments in advanced diagnostic platforms, increasing integration of digital health analytics. Major trends in the forecast period include increasing adoption of high-sensitivity troponin tests, rising use of point-of-care cardiac testing, growing demand for rapid diagnostic kits, expansion of multiplex cardiac biomarker panels, enhanced focus on early cardiac risk detection.

Global Cardiac Biomarkers Market Segmentation

1) By Biomarker Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA) 2) By Location Of Testing: Point Of Care Testing, Laboratory Testing 3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications 4) By End User: Hospitals, Specialty Clinics Subsegments: 1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels 2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels 3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels 4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels 5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

What Is The Driver Of The Cardiac Biomarkers Market?

The rise in healthcare expenditures is expected to propel the growth of the cardiac biomarker market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. Healthcare expenditure on cardiac biomarkers aims to improve early detection, personalized treatment, and efficient resource allocation, potentially reducing overall costs associated with cardiovascular diseases. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, in contrast to growth of just 0.9% in 2022. Therefore, the rise in healthcare expenditures is driving the growth of the cardiac biomarker industry.

Key Players In The Global Cardiac Biomarkers Market

Major companies operating in the cardiac biomarkers market are F. Hoffmann-La Roche AG, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Bio-Rad Laboratories Inc, bioMérieux SA, QuidelOrtho Corporation, Randox Laboratories Ltd, Becton Dickinson and Company, Tosoh Corporation, PerkinElmer Inc, Grifols S.A., DiaSorin S.p.A., Sysmex Corporation, Lepu Medical Technology (Beijing) Co. Ltd, Mindray Bio-Medical Electronics Co. Ltd, Fujirebio Holdings Inc, Euroimmun AG, Beckman Coulter Inc, Trinity Biotech plc

Global Cardiac Biomarkers Market Trends and Insights

Major companies operating in the cardiac biomarker markets are focused on developing innovative assays to expand their product portfolios to improve patient outcomes and address unmet medical needs. Innovative biomarker assays drive advancements in cardiac diagnostics, enhancing accuracy and expanding diagnostic capabilities. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a China-based medical devices and solutions provider company, launched two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs).

What Are Latest Mergers And Acquisitions In The Cardiac Biomarkers Market?

In December 2023, Mindray, a China-based medical devices company acquired DiaSys Diagnostic Systems GmbH for an undisclosed amount. With this acquisition, DiaSys will enhance Mindray's global competitive edge in In-vitro diagnostics by integrating DiaSys' capabilities and expanding its international reach. DiaSys Diagnostic Systems GmbH is a Germany-based diagnostic systems company specializing in in vitro diagnostics.

Regional Outlook

North America was the largest region in the cardiac biomarkers market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cardiac Biomarkers Market?

The cardiac biomarkers market consists of sales of assays and reagents, point-of-care testing (POCT) devices, instruments, and software solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.